137 related articles for article (PubMed ID: 18773608)
1. [Prevention of papillomavirus-associated cancer].
Signorelli C
Ann Ig; 2008; 20(3 Suppl 1):65-74. PubMed ID: 18773608
[TBL] [Abstract][Full Text] [Related]
2. Anti-HPV vaccination: a review of recent economic data for Italy.
Mennini FS; Costa S; Favato G; Picardo M
Vaccine; 2009 May; 27 Suppl 1():A54-61. PubMed ID: 19480963
[TBL] [Abstract][Full Text] [Related]
3. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
Thomas TL
Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
[TBL] [Abstract][Full Text] [Related]
4. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
Syrjänen KJ
Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
[TBL] [Abstract][Full Text] [Related]
5. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccine: a paradigm shift for pediatricians.
Jenson HB
Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
[TBL] [Abstract][Full Text] [Related]
8. Sexual behaviour in Ligurian (Northern Italy) adolescents and young people: suggestions for HPV vaccination policies.
Panatto D; Amicizia D; Lugarini J; Sasso T; Sormani MP; Badolati G; Gasparini R
Vaccine; 2009 May; 27 Suppl 1():A6-10. PubMed ID: 19480964
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of Human Papillomavirus (HPV) vaccination in the Netherlands: recent publication reinforces favorable cost-effectiveness despite misleading conclusion.
Postma MJ
Vaccine; 2010 Jan; 28(4):873-4. PubMed ID: 19896454
[No Abstract] [Full Text] [Related]
10. Structural differences among cost-effectiveness models of human papillomavirus vaccines.
Insinga RP; Dasbach EJ; Elbasha EH
Expert Rev Vaccines; 2008 Sep; 7(7):895-913. PubMed ID: 18767941
[TBL] [Abstract][Full Text] [Related]
11. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
12. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
13. Preparing for HPV vaccination in South Africa: key challenges and opinions.
Harries J; Moodley J; Barone MA; Mall S; Sinanovic E
Vaccine; 2009 Jan; 27(1):38-44. PubMed ID: 18977271
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
15. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
Dunne EF; Datta SD; E Markowitz L
Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
[TBL] [Abstract][Full Text] [Related]
16. Confirming our previous comments.
Garattini L; Casadei G
Vaccine; 2010 Jan; 28(4):880. PubMed ID: 19925905
[No Abstract] [Full Text] [Related]
17. Physicians' experiences with HPV vaccine delivery: evidence from developing country with multiethnic populations.
Wong LP
Vaccine; 2009 Mar; 27(10):1622-7. PubMed ID: 19100803
[TBL] [Abstract][Full Text] [Related]
18. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
[TBL] [Abstract][Full Text] [Related]
19. An assessment of the readiness for introduction of the HPV vaccine in Uganda.
Katahoire RA; Jitta J; Kivumbi G; Murokora D; Arube WJ; Siu G; Arinaitwe L; Bingham A; Mugisha E; Tsu V; LaMontagne DS
Afr J Reprod Health; 2008 Dec; 12(3):159-72. PubMed ID: 19435020
[TBL] [Abstract][Full Text] [Related]
20. Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer.
Keating KM; Brewer NT; Gottlieb SL; Liddon N; Ludema C; Smith JS
J Adolesc Health; 2008 Oct; 43(4 Suppl):S61-7. PubMed ID: 18809147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
